Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The World’s 1st Trial Testing Inhaled DMT Formulation

Stockhouse Editorial
1 Comment| April 27, 2022

{{labelSign}}  Favorites
{{errorMessage}}

This week, a biotech research and development company on the NEO Exchange commenced dose administration of the first subject in a Phase I/IIa clinical trial of its novel drug candidate BMND01, for treatment-resistant depression with inhaled administration.

Biomind Labs Inc. (BMND) (NEO.BMND, OTC: CRSWF, Forum) is developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules.

The Phase I/IIa clinical trial on Biomind's first innovative formulation of N,N-Dimethyltryptamine (DMT) is evaluating the safety, pharmacokinetics, behavioral and brain effects of BMND01, for inhaled administration.

The trial is being administered by medical practices at Biomind's new clinical psychedelic research facility in the University Hospital Onofre Lopes. Led by Biomind’s Scientific and Clinical advisor, Dr. Dráulio Araújo, the team is a renowned group of scientists that conducted the first randomized placebo-controlled trial with ayahuasca for treatment-resistant depression. This study is the world’s first clinical trial to test an inhaled formulation of DMT, Biomind’s novel drug candidate BMND01.

Speaking on this news for investors, Biomind CEO Alejandro Antalich said that the company's new psychedelic therapeutic model, as a psychiatry intervention-based approach, may allow a rapid and feasible merge of DMT therapy into clinical practices.

“Our intervention model has the capacity to be more easily integrated into existing mental health clinics worldwide, which will democratize the access to significantly more patients than the traditional psychedelic assisted therapy model.”

Dr. Araújo added that an inhaled formulation could allow DMT to be rapidly delivered directly into the systemic circulation, bypassing the first-pass metabolism, recognized as a major problem for some routes of DMT administration.

“Due to the chosen inhaled route of administration, the DMT is likely to exert plenty of its potency in approximately 10 minutes, which will allow more affordable interventions to be designed and implemented.”

FULL DISCLOSURE: Biomind Labs Inc. is a client of Stockhouse Publishing.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today